Showing posts with label Imatinib. Show all posts
Showing posts with label Imatinib. Show all posts
Friday, April 10, 2020

Dasatinib Tops Imatinib for Ph+ Acute Lymphoblastic Leukemia

›
In continuation of my update on  dasatinib and imatinib Dasatinib is associated with improved survival for pediatric patients with...
Monday, April 11, 2016

Bosutinib shows 'low' vascular, cardiac event risk profile

›
 In continuation of my update on  Bosutinib Third-generation tyrosine kinase inhibitor (TKI) study findings suggest that bosutinib i...
Thursday, July 2, 2015

Low doses of imatinib drug can push immune system to combat bacterial infections

›
In contiuation of my update on Imatinib Low doses of the anti-cancer drug imatinib can spur the bone marrow to produce more innate...
Tuesday, February 7, 2012

FDA Approves Gleevec for Expanded Use in Patients with Rare Gastrointestinal Cancer

›
In continuation of my update on imatinib... FDA Approves Gleevec for Expanded Use in Patients with Rare Gastrointestinal Cancer : The ...
Thursday, December 17, 2009

Nilotinib more efficiant over Imatinib for (Ph+ CML)....

›
Nilotinib ( see structure ) : Nilotinib , in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor, approved as Ta...
Monday, October 19, 2009

Imatinib for the treatment of Scleroderma ?

›
We know that Imatinib (its mesylate salt, Novartis) is a drug used to treat certain types of cancer. It is used in treating chronic myelog...